abrazo scottsdale campus ( formerly paradise valley hospital ) is an acute care hospital located in phoenix , arizona , in the united states .

abrazo scottsdale campus offers orthopedic services , sports medicines , rehabilitation services , diagnostic imaging , surgical weight loss procedures , women 's health services , da vinci surgical system , and 24-hour emergency care .

abrazo scottsdale campus

pca recovery full time days abrazo scottsdale description : abrazo scottsdale campus ( located at . . .
abrazo scottsdale campus . central sterile tech ft flex abrazo scottsdale campus : . abrazo scottsdale campus ( located at az - 51 and bell road in phoenix ) is a 136 . . .
abrazo scottsdale campus . patient sitter per diem rotating shift scottsdale campus . abrazo scottsdale campus ( located at az - 51 and bell road in phoenix ) is a . . .
abrazo scottsdale campus job type : . rn ed 10k sign on bonus full time nights scottsdale campus : . abrazo scottsdale campus ( located at az - 51 and bell road in . . .
abrazo scottsdale campus . med tech per diem day shift scottsdale campus . abrazo scottsdale campus ( located at az - 51 and bell road in phoenix ) is a 136 - bed full . . .
pca pool night medsurg scottsdale description : abrazo scottsdale campus ( located at az - 51 and . . .
pca pool day medsurg scottsdale description : abrazo scottsdale campus ( located at az - 51 and . . .
pca full time night 1k sign on medsurg scottsdale description : abrazo scottsdale . . .
“abrazo scottsdale campus is a small hospital so you get more personal attention , ” says abrazo scottsdale campus volunteer janet zupet . “it’s a very comforting and transparent and warm place . ”
abrazo scottsdale campus . abrazo scottsdale campus ( located at az - 51 and bell road in phoenix ) is a 136 - bed full - service acute care community - based hospital . . .
rn ed full time evenings central campus description : abrazo central campus ( located at 19th . . .
abrazo scottsdale campus and abrazo arizona heart hospital are offering free strokecheck events in may to raise awareness about stroke risk factors , symptoms and treatments .
the scottsdale independent is published monthly and mailed to 75 , 000 homes and businesses in scottsdale .
pca recovery full time days abrazo scottsdale description : abrazo scottsdale campus ( located at az - 51 and bell road in phoenix ) is a 136 - bed full - service acute care community - based hospital which . . .
pca pool night medsurg scottsdale description : abrazo scottsdale campus ( located at az - 51 and bell road in phoenix ) is a 136 - bed full - service acute care community - based hospital which has . . .
pca pool day medsurg scottsdale description : abrazo scottsdale campus ( located at az - 51 and bell road in phoenix ) is a 136 - bed full - service acute care community - based hospital which has provided . . .
pca full time night 1k sign on medsurg scottsdale description : abrazo scottsdale campus ( located at az - 51 and bell road in phoenix ) is a 136 - bed full - service acute care community - based hospital . . .
pca full time day 1k sign on medsurg central description : abrazo central campus ( located at . . .
arrowhead campus is an acute care 217 - bed hospital that has served the healthcare needs of northwest valley patients for two decades , arrowhead campus and its satellite , abrazo arizona heart hospital , are two of five hospitals in the abrazo community health network .
rn ed full time evenings central campus description : abrazo central campus ( located at 19th avenue and bethany home road in phoenix ) , a 221 - bed acute care facility and teaching hospital , has . . .
earlier this year , the joint commission in conjunction with the american heart association / american stroke association recognized abrazo scottsdale campus as a primary stroke center for achieving a high level of expertise in treating patients who arrive with symptoms of a stroke .
abrazo community health network is teaming up with the american heart association and the american stroke association to provide community education and health screenings including glucose checks from 9 a . m . to 1 p . m . may 6 at abrazo scottsdale campus , 3929 e . bell rd . in phoenix ; and 8 a . m . to noon may 18 at abrazo arizona heart hospital , 1930 e . thomas rd . in phoenix .
* * abrazo scottsdale campus * * ( located at az - 51 and bell road in phoenix ) is a 136 - bed full - service acute care community - based hospital which has provided excellent comprehensive medical care to patients in the northeastern region of metro phoenix for more . . .
welcome to abrazo arrowhead campus , where we believe that caring for you or your loved one is a privilege , and we are most grateful to you for trusting and choosing us .
abrazo arizona heart institute is solely dedicated to the prevention , diagnosis and treatment of heart and blood vessel disease . abrazo arizona heart institute , an affiliate of abrazo medical group , has board - certified specialists , including cardiologists , cardiothoracic surgeons , vascular surgeons , electrophysiologists , neurologists , pulmonologists and internists .
pca full time day 1k sign on medsurg central description : abrazo central campus ( located at 19th avenue and bethany home road in phoenix ) , a 221 - bed acute care facility and teaching hospital , . . .
with spacious labor and delivery rooms , private postpartum suites , and special care nurseries , abrazo west campus is committed to making the arrival of your newborn a joyous occasion . the special care physicians , nurses , and staff are dedicated to making every expectant mothers experience positive and memorable . at abrazo west campus , we are here to support you from the start . in advance of your visit , we offer informative childbirth classes and other educational opportunities to ensure your needs are met . upon arrival of your newborn , you will be provided robust resources to ensure any additional questions and concerns are answered . for more information about abrazo west campus , please visit : urltoken
the daily grind cafe in the outpatient area is excellent and extremely clean . the coffee is custom ground on the spot . in my opinion , it ' s better than starbucks . the lemon bars are top notch . gerry is very courteous , upbeat and helpful . this spot brings a ray of sunshine to abrazo scottsdale hospital campus . stop in .
at abrazo arrowhead campus , we want your experience as a patient or visitor to be as pleasant , convenient and comfortable as possible . we’re here to help you get well and get your life back to normal as quickly as possible .
physicians are members of the medical staff at one or more of abrazo ' s affiliated hospitals . however , some of these physicians are independent contractors who are neither employees nor agents of those hospitals or of abrazo , as a result , none of these hospitals nor abrazo is responsible for the acts of these physicians in their private medical practices .
abrazo medical group primary care and specialty physicians provide the highest quality of care for the entire family . abrazo medical group has 16 convenient locations and office hours to meet patient needs . physicians are contracted with most major insurance groups and new patients are always welcomed .
phoenix ( january 29 , 2014 ) - dignity health in arizona and abrazo health , two of the state’s largest health care organizations , further solidified a commitment to grow their accountable care footprint in arizona , with abrazo health signing an agreement enabling investment in the funding and expansion of arizona care network . under the terms of the agreement , abrazo health , which is owned by tenet healthcare corporation , will take a 50 percent ownership stake in the arizona care network .
about abrazo health as the second largest health care delivery system in arizona , abrazo health is committed to providing excellent medical care to the residents of maricopa county . the abrazo system includes six acute care hospitals : arrowhead hospital , maryvale hospital , paradise valley hospital , phoenix baptist hospital , west valley hospital and arizona heart hospital ; with a combined 1 , 029 licensed beds . in addition , the system consists of two health plans ; school - based health centers ; and abrazo medical group with 17 valley locations . abrazo health is owned by tenet healthcare corporation , a leading health care services company that through its subsidiaries operates 77 hospitals , 183 outpatient centers and conifer health solutions , a leader in business process solutions for health care providers serving more than 700 hospital and other clients nationwide .
at arrowhead campus , our highly qualified people – our experienced physicians , our skilled nurses and our dedicated support staff – make the positive difference in providing the best possible patient care . together , we relentlessly pursue excellence in medical quality and safety .
whether you need a specialty physician or a primary care doctor , both are important to your overall health and well - being . abrazo community health network is happy to help you find a physician within our system .
as part of the transaction , the two organizations are entering into a joint venture that will continue to grow the arizona care network and allow dignity health and abrazo health to more effectively pursue population health management arrangements to improve efficiency and patients’ outcomes and experience .
this directory lists physicians on abrazo community health network medical staff who choose to participate . the physician is solely responsible for the medical services provided to you . some listed physicians are employed by an affiliate of abrazo community health network , are participants in an accountable care organization , and / or offer on - line scheduling . the physicians in these categories are listed first in the rotation of providers who meet your search criteria . neither you nor the physician are charged for this service . if some physician reviews or ratings are shown , they are not the hospital’s opinions or endorsements ; they are public comments made to the zocdoc website , and are only provided for your ease of reference . if additional reviews are available for these physicians , you can find them at zoc doc website .
here ' s p . a . derek w burkum bullcrap response to amending my records ! he ' s so full of it , & i ' m filling against him & abrazo scottsdale campus to the arizona medical board . this is an unacceptable amendment in my eyes . i ' m not trying to be difficult , but for goodness sakes . let ' s get it straight derek . i ' m being honest , i don ' t appriciatte passive aggressively being called a liar . you claim you only write what you ' re told . but that ' s not what i told you !
so you ' re still calling me a liar .
you were obviously forced by higher ups to do this . because you refused amending it the first time . either that or kathy evans round filled it & denied it on her own . since none of my info was forwarded to the corporate office . which i was told by jill in corporate over a recorded line . so it ' s clear you ' re pissed about having to amend
your words
not mine ! but let ' s be real here buddy . i have no reason to lie ! there ' s nothing to gain by it ! you obviously have to keep your job . so yeah , you ' re gonna do whatever it takes . it pretty apparent in this document !
“this new joint venture will allow dignity health and abrazo health to be more competitive in the marketplace by establishing innovative , value - based care delivery contract arrangements with payers and employers focused on enhanced care coordination and improving the health status of our communities , ” said ken howell , ceo of tenet healthcare’s phoenix market . “tenet healthcare has a history of successful aco collaborations and we are pleased to continue advancing innovation in value based relationships care coordination through our integrated care networks . ”
“by collaborating with abrazo health , we have chosen to participate in a model of integration , which ultimately benefits all of the patients we serve , ” said linda hunt , president and ceo of dignity health in arizona . “utilizing both health systems’ deep relationships throughout arizona , we are creating an integrated health care delivery network that connects patients with physicians , care teams , and advocacy services . the network’s evidence - based clinical practices and quality standards are designed to drive the best possible outcomes for our patients . ”
this hospital carries an unfavorable reputation with many people i know , so i was a little nervous and wasn ' t sure what to expect when the time came to deliver my son . i am happy to say that the quality of care i received in labor and delivery , postpartum care , and the nursery exceeded my highest expectations . i delivered a healthy baby boy and both he and i were closely monitored by all staff - the nurses across the board are not only competent but wonderful and sweet . my epidural was expertly administered and i had no complications whatsoever . when the time comes to bring a second child into the world , i won ' t hesitate to deliver at abrazo again .
i had an emergency c section two months ago and was extremely grateful for the nursery during recovery ! all of the nurses in the maternity ward were prompt and personable . the room was large and you can control the temperature in it - which being a postpartum mom was extremely important to me . i overall had a fantastic experience and absolutely plan on having my future children at this hospital ! the maternity ward nurses were amazing ! i also chose this hospital because the ward was so much smaller than scottsdale shea honor health - this meant less patients , meaning better care in my case . i recommend this hospital to any expecting mothers - it ' s one of the only ones with a nursery , and trust me , after giving birth ( vaginally or c section , ) you ' re going to want the option to sleep before you go home . thank you to the maternity ward nurses for making my stay pleasant !
about arizona care network arizona care network is a physician - led , physician - governed accountable care organization and clinically integrated network that fosters collaboration and improved quality through shared resources , advanced technology and clinical best practices that align with emerging models of care delivery . this collaborative network aims to reduce costs , improve outcomes and provide a superior patient experience . composed of more than 2 , 000 physicians , nine acute care hospitals as well as more than half of all recognized patient centered medical home models in arizona , arizona care network is helping shape the future of health care through its progressive models of care delivery . arizona care network was formed through collaboration between dignity health and abrazo health , two market - leading organizations that have established relationships with strategic partners and premier health care providers throughout the state . for more information , see www . azcarenetwork . org .
wow . . . i felt so cared for ! ! having not been in a hospital overnight since having kids 25 + years ago . this entire staff from the er staff , whom made me feel so at ease , i ' m sorry i didn ' t take down all your names . to my nurses , may , rosy , alma # 1 & alma # 2 , patty who did the ultrasound of my heart to cory who did my stress test . thank you all ! never was my obesity brought up to make me feel uncomfortable , these people are top notch ! ! and they offered every service i needed to complete and assure me that my heart was good and healthy ! each and every one of you went out of your way to make sure i was comfortable and i can ' t thank you enough - please know i appreciated you all very much ! if there is a way for me to let your boss ' s or a ceo of abrazo know , please give me the information , i have told everyone about my great experience , if you can say that when going to an er with chest pains , and i can after experiencing this with you all ! thank you from the top & bottom of my heart ! ! - candice yatsinko , cottonwood , az
please note : due to the number of entrants in every category – the system may take a moment to load each page . thank you for your patience .
please note : you can click the “blue down arrow” next to a category to reveal sub - categories .
step 1 : you will register your email one time by clicking on “already entered ? ” in the teal box .
you may need to check your junk folder and approve the address so it will go to your inbox . the login will be good for 90 days then
step 2 : select one of the 10 main categories . please note : you can click the “down arrow” next to a category on the left to reveal sub - categories .
step 4 : click on a company name and click the green vote button . upon completion you will receive a notification that thanks you for nominating , which means you voted . the system will then automatically suggest you vote in the next category or you may select a different category from the list on the left .
you may vote for one company in each sub - category once per - hour .
if a company is not listed and you would like to nominate them , scroll to the bottom of the entrants list where you’ll see the question “don’t see your favorite ? ” and type the company you would like considered , select continue to complete the submission . please be mindful of which category you are currently in . nominations in incorrect categories may take longer to process and are not available immediately to vote for . please allow 3 - 5 business days for new nomination approvals .
note : when voting , ensure the browser you are using ( fire fox , google chrome , safari , or edge ) allows cookies ( third party ) or you will find that you cannot proceed to vote .
each category is selected by the staff of az big media for the general public to vote on and is based upon business and leisure activities of arizona’s business professionals .
please ignore this text box . it is used to detect spammers . if you enter anything into this text box , your message will not be sent .
in its deal for vanguard health systems , dallas - based tenet healthcare corp . is also getting “the best acquisition team” in the industry , company president and ceo trevor fetter said .
and he quickly plans to put that team — paired with tenet’s own acquisition specialists — to work .
“we’re very interested in expanding in markets we serve and expanding into new markets with scale , ” fetter said in an interview .
tenet said tuesday that it had completed the deal with nashville - based vanguard , announced in june . the company , which operates around the country , now employs more than 100 , 000 people and has 77 acute care hospitals , 173 outpatient centers , five health plans and six accountable care organizations .
annual revenue will be between $ 15 billion and $ 16 billion , fetter said .
tenet paid $ 21 a share for vanguard stock and assumed $ 2 . 5 billion of vanguard debt , making the total value of the deal $ 4 . 3 billion .
fetter was especially pleased with the terms his company secured for financing the deal . tenet priced a total of $ 4 . 6 billion in secured and unsecured notes at interest rates of 6 percent and 8 . 13 percent .
“the company has been in business 45 years , and these are the cheapest rates at which we have ever borrowed money , ” fetter said . “it’s amazing how great the markets have been . ”
completion of the vanguard deal came on the same day the insurance exchanges debuted and a day after dallas - based baylor health care system and temple - based scott & white healthcare completed their merger , creating the largest not - for - profit health system in texas .
as the affordable care act moves to full implementation , this is a time of great change in the industry . more patients will be covered by insurance , but reimbursements from medicare and medicaid , which cover the elderly and poor , will be lower .
“it went a lot faster than we anticipated , ” he said of gaining approval from state regulators where the company operates .
in the deal , tenet acquires hospitals in san antonio and south texas , which will double the company’s annual revenue in texas to $ 3 billion .
he said tenet alone ranked first or second in 14 markets , about 60 percent of the places it operated . the merged company ranks first or second in 19 markets , or 70 percent of the places it operates , he said .
“when we go into new markets , we would have to be in a very strong position … or see a pathway to building a strong position , ” fetter said .
vanguard was especially adept at acquiring not - for - profit hospitals , and fetter sees them as candidates for acquisition .
“about 80 percent of all hospitals are not - for - profit , ” he said .
in trading tuesday , tenet stock closed at $ 41 . 37 a share , up 18 cents . vanguard stock no longer trades .
our community is growing , and with that comes a greater demand for medical care . like most hospitals , we offer a broad range of services to meet your needs when you walk through our doors . unlike other hospitals , we offer those services with the human touch that only a smaller community hospital can provide . that means less frustration for you .
linda curry was driving her daughter home when she fell unconscious at the wheel without any warning signs . linda didn’t have a pulse and was experiencing a full cardiac arrest . read
she’s not paid to say that . she sees it every day as a volunteer .
because it never hurts to be recognized for excellence , we were named a top performer on key quality measures by the joint commission , a recognition of exemplary performance in using clinical processes that improve care .
let us help you find what you ' re looking for . call us at ( 877 ) 934 - 9355 or fill out the form below .
if you have a potentially life - threatening medical emergency , please call 911 .
get our advice and upcoming events about weight , pain , heart and more . select the topics that interest you .
select a specialty * or use the advanced search options to refine your search . you must select a specialty , unless you are searching by last name of physician .
call our toll free physician referral service line at 1 - 877 - 934 - 9355 to find a physician nearest you .
there are no classes currently scheduled for all services . please check back at a later date .
first , try refreshing the page and clicking current location again . make sure you click allow or grant permissions if your browser asks for your location . if your browser doesn ' t ask you , try these steps :
at the top of your chrome window , near the web address , click the green lock labeled secure .
in the window that pops up , make sure location is set to ask or allow .
you ' re good to go ! reload this yelp page and try your search again .
if you ' re still having trouble , check out google ' s support page . you can also search near a city , place , or address instead .
at the top of your opera window , near the web address , you should see a gray location pin . click it .
if you ' re still having trouble , check out opera ' s support page . you can also search near a city , place , or address instead .
click safari in the menu bar at the top of the screen , then preferences .
under website use of location services , click prompt for each website once each day or prompt for each website one time only .
macos may now prompt you to enable location services . if it does , follow its instructions to enable location services for safari .
close the privacy menu and refresh the page . try using current location search again . if it works , great ! if not , read on for more instructions .
back in the privacy dialog , click manage website data . . . and type urltoken into the search bar .
you ' re good to go ! close the settings tab , reload this yelp page , and try your search again .
if you ' re still having trouble , check out safari ' s support page . you can also search near a city , place , or address instead .
at the top of your firefox window , to the left of the web address , you should see a green lock . click it .
in the window that pops up , you should see blocked or blocked temporarily next to access your location . click the x next to this line .
you ' re good to go ! refresh this yelp page and try your search again .
if you ' re still having trouble , check out firefox ' s support page . you can also search near a city , place , or address instead .
click the gear in the upper - right hand corner of the window , then internet options .
uncheck the box labeled never allow websites to request your physical location if it ' s already checked .
you ' re good to go ! click ok , then refresh this yelp page and try your search again .
at the top - right hand corner of the window , click the button with three dots on it , then settings .
click show more , then make sure only the box labeled location permissions is checked .
oops ! we don ' t recognize the web browser you ' re currently using . try checking the browser ' s help menu , or searching the web for instructions to turn on html5 geolocation for your browser . you can also search near a city , place , or address instead .
something broke and we ' re not sure what . try again later , or search near a city , place , or address instead .
we couldn ' t find you quickly enough ! try again later , or search near a city , place , or address instead .
we couldn ' t find an accurate position . if you ' re using a laptop or tablet , try moving it somewhere else and give it another go . or , search near a city , place , or address instead .
my son broke his clavicle during football and i took him in to confirm it . pam , carole and z . jeffrey were amazing ! x - ray , sling , pain medication and he was out the door . it was quick , we were diagnosed fast , we had the right amount of attention and they got back to helping really sick patients . i can ' t thank the staff enough .
i think the nurses in er are the best . where i had my problem was the so called cardiologist who really could tell me nothing . i really am in still . in a lot of pain and i feel nobody cared except the older er nurse . i would like to speak to a admin patient advocate . they need some work in the way they talk to people . please contact me asap
so i preregistered online for the emergency room and even got here about 30 minutes before that time . it is now 3 hours later and the only thing that has been done , was i was triaged and then sent back out into the lobby . i asked the person at the window after 2 hours how long of a wait it would be , and was told
i ' ll ask the nurses .
it ' s been another hour since then , i ' m the only person in the waiting room , and don ' t see an end in sight . i overheard them tell another patient that even if they left , they would still be charged because triage has already been done . this is ridiculous and there is no reason that an emergency room with less than 5 patients at 3 : 30 pm should still have a patient waiting to be seen at 6 : 4never again . well at 7 : 30 i was finally brought to the back where i waited another 3 hours before i was told that i would need to be transferred to another hospital . i ended up wasting about 8 hours of my time just to be told that they couldn ' t help me . so i was transported by ambulance to a much better facility at st . joseph ' s . i will say , once again , i will never set foot in this facility again .
i was so disappointed in this place . i called ahead and talked to them about bringing my son who had choked on a piece of steak and the steak was still stuck in his throat . after being told to bring him in , i checked him into the er , they walked us down to a room and immediately told me that he would need to go to phoenix children ' s hospital . i was so upset that they allowed me to check in . they wanted to transport him by ambulance . which i didn ' t allow , instead i drove him straight to phoenix children ' s and they admitted him . 2 weeks later i get a bill from abraso for almost $ 500 . we were there for 20 mins tops . and they did nothing ! ! if you have a child that needs to go to the hospital take them straight to phoenix children ' s don ' t bother with this hospital .
i really want to give this place 5 stars , the staff was very friendly , place was clean , we had no issues . but unfortunately they randomly assigned to us a
provider
during the birth of our child that was out - of - network with our insurance company without letting us know or giving us the option to choose a different pediatrician immediately after the birth . great place but if you are having a baby proceed with caution and ask about all of the providers who may interact with your family and provide services . some of them may just be out - of - network . do your research , ask the questions . it will be ultimately your financial responsibility .
heard bad things about this hospital , but was worse than i imagined . er staff unfeeling , not thorough , just in hurry to discharge . even had to ask for bandages for my cut hands as i was being discharged . no instructions , not concerned at all . worst hospital ever ! ! should have listened to everyone who warned me not to go there . dont go to this hospital ! period .
get rid of your er check in time because it literally means nothing . i ' ve now been waiting for going on 2 hours for my 630 check in time and i was told
well those times don ' t actually mean anything . it ' s the time you get to the hospital .
really ? ! because that ' s literally what it says . check in and wait at home . nope ! not here . another lady here had a 545 check in and she is still waiting . it ' s 820 .
my dad was recently sent there for heart issues they ended up doing a stent to open up arteries he had a heart attack during the procedure . they revived him and spent 3 days in icu . the nurses were great in icu . but they released him to soon to a regular room per the cardiologist . he ended up getting aspirated pneumonia after that . then released him after a week . they transferred him to a acute care center and was there 24 hours and had to go back in the hospital . but not back to this one . the care he received in his normal room was just adequate and ended up getting pneumonia because of it . the nurse on his 1st day in his normal room could never be found . am care was below average case management staff was excellent .
incredibly happy with every nurse that helped my wife during her labor and the delivery of our baby girl . during her 3 day stay , each of her assigned nurses kept her very comfortable and was always there when we needed them . the hospital was very quiet each day and night . our family had a private waiting room all to them selves . the staff maid my wife and i feel very special , as if we were their only priority . could not have been more comfortable .
if i could give this hospital 0 stars i would . absolutely the worst hospital out there . i hurt my wrist and barely could move it and all they did was prescribe me ibuprofen , give me a sling and was told to call my primary doctor tomorrow . i was treated as a
number
rather then a patient . i ended up going to the mayo clinic that very same night where i was treated like a patient and got x - rays . so caring compared to this crap hospital . this isn ' t the first time this has happened to me here either . all they want is your money . they don ' t care about your health , they want you out as fast as possible . if you are hurt and want legitimate answers , do yourself a favor and go elsewhere .
i am so happy with the care that my friend is getting the best care by dr . jalal and his team . icu 3rd floor was amazing . joe really cared for paul . nurse brenda on the 3rd floor is the best ! ! ! maria is so good to paul . i can ' t be there all the time . someone has to work ! ! ! ' keep up the great work . the nurse who gave paul his pills this morning was so gentle , i appreciate all of you . i deleted all my negative posts .
came here for their wound care clinic after a nasty bought of cellulitis . dr sekowsky was knowledgeable and always clearly answered my questions . took very good care of my wound . at first i didn ' t want to come to this location when referred by my doctor because of bad experiences with this hospital many years ago . this experience helped change my mind .
i went for an outpatient procedure , and as i recovered from anesthesia , the hopital staff told me oops a machine we used on you was not cleaned properly and you may be exposed to hiv , hep c , hep b etc ! ! ! ! ! they took 4 vials of blood and said they will follow up by the end of the week . i never heard from for 2 weeks until after the dr who performed the procedure called them and asked wtf ? they were apologetic and flaky and then told me it was low risk so i could just forget about further blood tests ? ! hell no , this is my life and i will have to take blood tests for the next six months now to be sure i am in the clear . i will never set foot in this shit show hospital ever again and i recommend you avoid this dump like the plague . unless you want the plague ?
“they also offer great additional services that were important to me like a fantastic lactation consultant who also does follow free follow up visit . ” in 3 reviews
“ several nurses came in and out while i was in a room , and each asked me if i was comfortable or would like to watch tv . ” in 2 reviews
“i am happy to say that the quality of care i received in labor and delivery , postpartum care , and the nursery exceeded my highest expectations . ” in 7 reviews
your trust is our top concern , so businesses can ' t pay to alter or remove their reviews . learn more .
heads up : from now on , other yelpers will be able to see how you voted . want to chime in ?
we take patient complaints very seriously and would like to follow up with you directly . please…
we take patient complaints very seriously and would like to follow up with you directly . please email your contact information to patientexperience @ teneth… .
so i preregistered online for the emergency room and even got here about 30 minutes before that time . it is now 3 hours later and the only thing that has been done , was i was triaged and then sent back out into the lobby . i asked the person at the window after 2 hours how long of a wait it would be , and was told
i ' ll ask the nurses .
it ' s been another hour since then , i ' m the only person in the waiting room , and don ' t see an end in sight . i overheard them tell another patient that even if they left , they would still be charged because triage has already been done . this is ridiculous and there is no reason that an emergency room with less than 5 patients at 3 : 30 pm should still have a patient waiting to be seen at 6 : 45 pm . never again .
we ' re very sorry to hear about your experience , sarah . we will address this with the appropriate…
we ' re very sorry to hear about your experience , sarah . we will address this with the appropriate departments .
denise , your feedback matters to us . this will be addressed with hospital leadership .
thank you for reaching out to us , aidan . we will look into this situation right away .
well i messaged you , of course there ' s no response either . there ' s no doubt you all don ' t care…
well i messaged you , of course there ' s no response either . there ' s no doubt you all don ' t care about your patients or there community .
went to this e . r . on xmas eve for a cut to my fingers . i was asked what happen . so i proceeded to…
thank you for reaching out to us again , kenny . you should receive a letter from the department…
thank you for reaching out to us again , kenny . you should receive a letter from the department director who can assist you further shortly .
hi lisa , we are sorry to hear about your experience , but appreciate you voicing your concerns . we…
hi lisa , we are sorry to hear about your experience , but appreciate you voicing your concerns . we will address your concerns with hospital leadership immediately .
thank you for your feedback , eric ! we will pass along your kind words .
hi b w , we ' re committed to providing high - quality care and patient satisfaction . your feedback is…
hi b w , we ' re committed to providing high - quality care and patient satisfaction . your feedback is important and we would like to speak to you personally . we are going to send you a private message . thank you .
i am so happy with the care that my friend is getting the best care by dr . jalal and his team . icu…
i am so happy with the care that my friend is getting the best care by dr . jalal and his team . icu 3rd floor was amazing . joe really cared for paul . nurse brenda on the 3rd floor is the best ! ! ! i deleted all my negative posts .
we calculate the overall star rating using only reviews that our automated software currently recommends .
so i preregistered online for the emergency room and even got here about 30 minutes before that time . it is now 3 hours later and the only thing that has been done , was i was triaged and then sent . . .
read more read { { review . expanded ? ' less ' : ' more ' } }
i was so disappointed in this place . i called ahead and talked to them about bringing my son who had choked on a piece of steak and the steak was still stuck in his throat . after being told to . . .
my son broke his clavicle during football and i took him in to confirm it . pam , carole and z . jeffrey were amazing ! x - ray , sling , pain medication and he was out the door . it was quick , we were . . .
i think the nurses in er are the best . where i had my problem was the so called cardiologist who really could tell me nothing . i really am in still . in a lot of pain and i feel nobody cared . . .
i really want to give this place 5 stars , the staff was very friendly , place was clean , we had no issues . but unfortunately they randomly assigned to us a
provider
during the birth of our child . . .
tip : enter your city or zip code in the
where
box to show results in your area .
what is the vacation policy like ? how many vacation days do you get per . . .
as a part of the tenet and catholic health initiatives family , conifer health brings 30 years of healthcare industry expertise to clients in more than 135 . . .
please note that all salary figures are approximations based upon third party submissions to indeed . these figures are given to the indeed users for the purpose of generalized comparison only . minimum wage may differ by jurisdiction and you should consult the employer for actual salary figures .
healthgrades ratings show you how well a hospital performed in providing patient care . when receiving treatment for a specific condition or undergoing a specific procedure in the hospital , you want the best care possible . you lower your risk of experiencing a negative outcome by selecting a five - star hospital .
all hospitals strive to offer great medical care - - but some do a better job than others . use healthgrades to research hospital performance and talk to your doctor about what ' s right for you .
coronary interventional procedures are minimally invasive procedures , such as angioplasty , that open narrowed or blocked coronary arteries ( blood vessels of the heart ) to restore normal blood flow to the heart muscle .
all hospitals strive to offer great medical care—but some do a better job than others . use healthgrades to research hospital performance in coronary interventional procedures and talk to your doctor about what’s right for you .
a heart attack is a life - threatening condition in which your heart muscle is deprived of oxygen . a heart attack , usually caused by a blood clot , causes serious damage to your heart muscle and its ability to function effectively .
all hospitals strive to offer great medical care—but some do a better job than others . use healthgrades to research hospital performance in treating heart attack patients and talk to your doctor about what’s right for you .
heart failure , or congestive heart failure ( chf ) , occurs when your heart is damaged and too weak to pump enough oxygen - rich blood to the body . fluid pools in your body’s tissues , causing swelling and life - threatening lung congestion .
all hospitals strive to offer great medical care—but some do a better job than others . use healthgrades to research hospital performance in treating patients with heart failure and talk to your doctor about what’s right for you .
complications based rating on 52 hospital cases and a national average of 156 cases .
pacemaker procedures include surgery to implant or replace a pacemaker—an electronic device that treats heart rhythm problems , mainly in the upper chambers ( atria ) . a pacemaker sends low - energy electrical pulses to restore a normal heart rhythm .
all hospitals strive to offer great medical care—but some do a better job than others . use healthgrades to research hospital performance in pacemaker procedures and talk to your doctor about what ' s right for you .
notice : use of this website and any information contained herein is governed by the healthgrades user agreement .
diabetic emergencies include hypoglycemic shock and diabetic ketoacidosis ( dka ) and coma . both conditions are life - threatening complications of diabetes . hypoglycemic shock occurs when blood sugar gets too low . dka occurs when your body produces high levels of blood acids called ketones , which can lead to coma .
all hospitals strive to offer great medical care—but some do a better job than others . use healthgrades to research hospital performance in treating patients with diabetic emergencies and talk to your doctor about what’s right for you .
a pulmonary embolism is a blockage in an artery in the lungs . a pulmonary embolism is a potentially life - threatening condition that is usually caused by a blood clot that travels to the lung from a vein in the leg .
all hospitals strive to offer great medical care—but some do a better job than others . use healthgrades to research hospital performance in patients with a pulmonary embolism and talk to your doctor about what’s right for you .
respiratory failure is a life - threatening condition that occurs when the respiratory system fails to supply enough oxygen to the body or remove carbon dioxide waste from the body .
all hospitals strive to offer great medical care—but some do a better job than others . use healthgrades to research hospital performance in treating patients with respiratory failure and talk to your doctor about what’s right for you .
sepsis is caused by any serious infection that spreads through the bloodstream and results in potentially life - threatening inflammation throughout the body .
all hospitals strive to offer great medical care—but some do a better job than others . use healthgrades to research hospital performance in treating patients with sepsis and talk to your doctor about what’s right for you .
a bowel obstruction , also called intestinal obstruction , is a blockage of the bowel ( intestine ) that prevents passage of intestinal material .
all hospitals strive to offer great medical care—but some do a better job than others . use healthgrades to research hospital performance in treating patients with bowel obstruction and talk to your doctor about what’s right for you .
colorectal surgeries correct problems of the colon ( large intestine ) and rectum . surgeries include full or partial removal ( resection ) of the colon or rectum ; removal of the left or right side ( hemicolectomy ) , the lower part ( sigmoidectomy ) , or the upper part ( cecectomy ) of the colon ; and attaching the colon to an opening ( stoma ) in the abdominal wall ( colostomy ) .
all hospitals strive to offer great medical care—but some do a better job than others . use healthgrades to research hospital performance in colorectal surgeries and talk to your doctor about what’s right for you .
esophageal and stomach surgeries correct problems of the esophagus and stomach , including bleeding and ulcers . surgeries include full or partial removal of the stomach ( gastrectomy ) , removal of the vagus nerve responsible for stomach acid ( vagotomy ) , and intestine resection and anastomosis .
all hospitals strive to offer great medical care—but some do a better job than others . use healthgrades to research hospital performance in esophageal / stomach surgeries and talk to your doctor about what’s right for you .


algeta asa ( algeta : no ) was founded in 1997 by roy h. larsen and øyvind s. bruland in oslo , norway as a private biotechnology and pharmaceutical company .

the company ’s research and development focus lies in the field of alpha-particle emitting radiopharmaceuticals .

the lead product of the company , xofigo is the first marketed alpha-particle emitting radiopharmaceutics for cancer treatment .

algeta

a fund that is the company’s largest shareholder and senior algeta managers , together representing 14 percent of algeta’s share capital , planned to accept , algeta said .
“we believe the offer recognizes the strategic value of algeta and delivers a considerable cash premium to our shareholders . ” stein holst annexstad , algeta’s chairman , said .
7 . buyer : bayer target : algeta price : $ 2 . 9 billion
bayer wins cancer firm algeta with raised $ 2 . 9 billion bid | reuters
algeta said on thursday that its board unanimously recommended shareholders accept bayer’s sweetened offer .
for more : fda oks pinpoint prostate cancer radiation drug xofigo from bayer , algeta bayer bags algeta ' s cancer drug portfolio for $ 2 . 9b bayer ' s $ 2 . 4b bid to buy algeta fits neatly with cancer drug strategy
bayer bags algeta ' s cancer drug portfolio for $ 2 . 9b | fiercebiotech
an algeta buyout , though , would fall right into bayer ' s comfort zone .
bayer in talks to buy cancer partner algeta for $ 2 . 4 billion - livemint
algeta us and bayer healthcare are co - promoting the product in the us . bayer paid a €50m milestone payment to algeta following the launch of the product in the us .
algeta was advised by bioscience managers limited ( london , uk ) during this financing round .
bayer to acquire norway ' s algeta for cancer drug xofigo in $ 2 . 9b deal
bayer to acquire drug maker algeta in $ 2 . 9 billion deal - the new york times
stein holst annexstad , chairman of the board of directors of algeta , added : ' we believe the offer recognises the strategic value of algeta and delivers a considerable cash premium to our shareholders .
) has won backing from the board of algeta algeta . ol , its partner for a new prostate cancer treatment , for an increased $ 2 . 9 billion offer to buy the norwegian company .
shares of algeta rose 1 . 5 percent to 359 norwegian kroner in trading early tuesday in oslo .
updated : bayer ' s $ 2 . 4b bid to buy algeta fits neatly with cancer drug strategy
algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha - pharmaceutical platform . the company is headquartered in oslo , norway , and has a us subsidiary , algeta us , llc , based in cambridge , ma performing commercial marketing operations in the us . algeta is listed on the oslo stock exchange ( ticker : algeta ) . for more information please visit urltoken .
bayer to acquire norway ' s algeta for cancer drug xofigo in $ 2 . 9b deal | ubc
algeta’s largest shareholder , the venture capital firm healthcap , and algeta’s directors have agreed to tender their shares . the transaction is subject to regulatory approval and shareholders must tender a minimum of 90 percent of the company’s stock .
goldman sachs is algeta’s financial adviser , and skadden , arps , slate , meagher & flom and wikborg , rein & co . are acting as algeta’s legal advisers . deutsche bank served as bayer’s financial adviser on the transaction .
algeta scientists showed that injections of radium into the blood led to a concentration in bone and a positive impact on patient survival . from 2004 , abingworth followed algeta closely before leading a major recapitalisation of the company in 2009 .
updated : bayer ' s $ 2 . 4b bid to buy algeta fits neatly with cancer drug strategy | fiercebiotech
) has clinched a $ 2 . 9 billion deal to take over norwegian cancer drug maker algeta algeta . ol after being tendered 92 . 17 percent of the shares in a cash offer , the companies said on monday .
bayer has reached an agreement to buy norwegian pharma company algeta after raising its offer to around $ 2 . 9bn .
bayer’s increased bid is at a 48 percent premium to algeta’s three - month volume weighted average stock price on november 25 .
the offer , which is expected to go to algeta shareholders in january once it has been cleared by the oslo stock exchange , is subject to a minimum acceptance of 90 percent of algeta’s share capital , as well as approval by antitrust authorities .
management of the two companies have now agreed a nok 362 per share deal for algeta , which will now be offered on a voluntary basis to the norwegian firm ' s shareholders . the bid represents a premium of 37 per cent over algeta ' s closing price on november 25 when the initial offer was made . this morning algeta was trading at around nok 359 .
bayer is offering algeta shareholders a smaller premium than other biotechnology companies have gotten over the past five years . photo : bloomberg
algeta is also developing other technologies for delivering alpha - pharmaceuticals . these include methods to enhance the potency of therapeutic antibodies and other tumor - targeting molecules by linking them to the alpha particle emitter thorium - 227 . the company is headquartered in oslo , norway , and was founded in 1997 . algeta listed on the oslo stock exchange in march 2007 ( ticker : algeta ) .
- potential deal value of $ 800 million ( eur560m * ) plus tiered double digit royalties - algeta to receive $ 61 million ( eur42 . 5m ) cash upfront , followed by development and sales milestones - algeta retains option for co - promotion and profit - sharing in usa - algeta and bayer will jointly develop alpharadin , with bayer contributing a substantial majority of the costs of future development
in september 2009 , algeta entered into an global agreement with bayer healthcare ag for the development and commercialization of alpharadin . as part of the agreement , algeta retains an option to co - promote alpharadin in the united states and to share profits from future sales .
algeta asa ( ose : algeta ) , the cancer therapeutics company , announces today that it has entered into a global agreement with bayer for the development and commercialization of algeta ' s first - in - class alpha - pharmaceutical , alpharadin . alpharadin is currently being evaluated in a global phase iii trial in men with hormone - refractory prostate cancer ( hrpc ) that has spread to the bone .
the uk future technologies fund contributed to the fund . in addition to avila advent has backed cellnovo , respivert , thiakis and algeta .
bayer has won the backing of the board of directors of algeta to support its bid to acquire the norwegian developer of cancer drugs .
algeta asa is a cancer therapeutics company built on world - leading , proprietary technology . algeta is developing a new generation of targeted cancer therapeutics ( alpha - pharmaceuticals ) that harness the unique characteristics of alpha particle emitters and are potent , well - tolerated and convenient to use .
“when the company was bought by bayer , there were a lot of competencies and resources that were allocated to other promising companies . so other companies can capitalize on [ the worked performed in algeta ] . the inventors of algeta have started two new companies , ” benedicte bakke explains .
the bayer group plans to further strengthen its oncology portfolio with the acquisition of norwegian pharmaceutical company algeta asa , oslo , according to a press release . bayer has already collaborated with algeta to develop and commercialize the cancer drug xofigo . the planned acquisition would give bayer full control over xofigo .
the first commercial sale of xofigo triggers a eur 50 million milestone payment to algeta from bayer under the terms of the 2009 development and licensing agreement . bayer has worldwide exclusive marketing rights for xofigo . algeta us , llc and bayer healthcare are co - promoting the product in the us .
in september 2009 , algeta signed an agreement with bayer for the development and commercialization of xofigo . under the terms of the agreement , bayer will develop , apply for health authority approvals worldwide and commercialize xofigo globally . algeta us , llc is co - promoting xofigo with bayer in the us .
algeta said in march that there was broad industry interest in its thorium - 227 technology . thorium - 227 is an alpha - particle emitting element that can be linked to monoclonal antibodies to create localized tumor - killing cancer treatments . algeta is working with sanofi , ablynx nv , affibody ab and
for bayer , algeta fits with chief executive marijn dekkers’ strategy of driving growth by building up the pharmaceuticals division , which now overshadows chemicals in importance .
oslo , norway - - march 26 , 2007 - - algeta asa , the norwegian cancer therapeutics company , today announced the successful closing of its initial public offering . the offering was more than two times oversubscribed and was priced in the upper half of the price range at nok 47 per share . gross proceeds ( before over - allotment ) amount to nok 250 million ( $ 41 million ) . the offering took place in conjunction with algeta’s listing on the oslo stock exchange . algeta shares are expected to begin trading on the oslo stock exchange ( ticker : algeta ) on tuesday , 27 march 2007 .
algeta won the scrip award for biotech of the year in 2010 on the basis of it signing one of the largest partnering deals of the year in oncology with bayer . algeta also won breakthrough of the year at the european mediscience awards in 2012 following its successful phase 3 results and progress towards launch .
norwegian biotech algeta asa has licensed bayer schering pharma worldwide development and marketing rights to its phase iii cancer - targeting radiopharmaceutical alpharadin ( radium 223 chloride ) .
xofigo project name : radium - 223 chloride disease : prostate cancer peak sales estimate : $ 1 . 5 billion approved : may 15 companies : bayer and algeta
in september 2009 , algeta signed an agreement with bayer for the development and commercialization of radium - 223 . under the terms of the agreement , bayer will develop , apply for health authority approvals worldwide and commercialize radium - 223 globally . algeta us , llc will co - promote radium - 223 with bayer in the us .
bayer’s sweetened bid at 362 norwegian crowns per share represents a 37 percent premium to algeta’s closing price on november 25 , the day before its initial offer became public .
advent invested in the series a in 2005 . algeta listed on the oslo stock exchange in march 2007 and was acquired by bayer in 2014 for $ 2 . 9b .
she points , for example , to the major investment fund healthcap , which is also a member of the cluster and has posted millions in both nordic nanovector and algeta .
from the left : andrew kay , ceo of algeta , trond giske , the norwegian trade and industry minister and eva dugstad , president of ife . photographer : ina wesenberg
the alpharadin deal with bayer totals up to $ 800 million ( eur560m ) to algeta . this is made up of an upfront payment of $ 61 million ( eur42 . 5m ) plus further cash payments based upon the achievement of certain development , production and commercialization milestones . algeta will be responsible for manufacturing and supply of the commercial product .
still , after bayer put down a 14 . 8 billion kroner ( $ 2 . 4 billion ) bid for oncology partner algeta , some analysts immediately predicted an uptick in price . algeta discovered xofigo , the recently approved radiotherapy for prostate cancer that has spread to the bone - - and bayer has pegged it as a $ 1 billion - plus drug . plus , algeta is working on more radiation - based cancer technologies , including an armed - antibody approach , and bayer wants to beef up its offerings in oncology .
algeta said on thursday that bayer , through a subsidiary , intends to launch a cash tender offer to acquire the outstanding stock of the company for 362 norwegian kroner , or about $ 59 . 13 , a share . the offer is a 37 percent premium on algeta’s closing price on nov . 25 , the day before the preliminary offer was announced .
the board of directors of algeta has unanimously decided to recommend acceptance of the offer to its shareholders . in addition , bayer has obtained pre - acceptances for approximately 14 % of the shares in algeta , including pre - acceptances from all members of algeta’s board of directors as well as from algeta’s largest shareholder , healthcap iv . bayer intends to make the offer through a subsidiary of bayer nordic se once the offer document has been cleared by the oslo stock exchange . the successful completion of the transaction is subject to certain conditions , including a minimum acceptance level of 90 % of the share capital and approval by the relevant antitrust authorities . bayer expects to close the transaction during the first quarter of 2014 .
the statement reinforces the view that bayer views the algeta acquisition as a platform rather than a product purchase , with additional radiopharmaceuticals in its pipeline including a programme in breast cancer .
‘ife has been an important partner to algeta throughout the clinical development of radium 223 , and it has been instrumental in helping us build a commercial production facility for the global supply of xofigo . we are all extremely grateful for the expertise , dedication and support that ife has provided to algeta on this journey and look forward to continuing our productive partnership . ’
algeta asa is a norwegian therapeutics company built on world - leading expertise in nuclear medicine and oncology and dedicated to the development of novel anticancer therapeutics based on alpha particle emitting radionuclides .
having worked with bayer since 2009 , the board of directors is convinced of bayer ' s commitment to establishing xofigo ( radium ra 223 dichloride ) globally , and maximizing its blockbuster potential ,
noted algeta chairman stein holst annexstad .
we are also pleased that bayer intends to further invest in the potential of algeta ' s targeted thorium conjugate research platform .
algeta received a preliminary offer for 336 kroner a share , the oslo - based drugmaker said in a statement on tuesday , following a report on the approach by german newspaper frankfurter rundschau . the proposal values algeta at 27 % more than monday’s closing price of 264 . 6 kroner . the shares rose to 345 . 20 kroner , suggesting investors expect a higher bid .
upfronts , milestones and royalty payments according to the agreement between bayer and algeta will be in eur . usd amounts provided in this release have been translated at 1 euro : usd1 . 43
bayer’s shares were up 1 percent , while algeta’s rose 1 . 5 percent by 5 : 21 a . m . et in line with the stoxx europe 600 health care index . sxdp .
bayer acquired the drug through an $ 800 million deal with norway ' s algeta in 2009 , and the german pharma magnate is now hitching its oncology hopes to its partner ' s platform technology , paying $ 2 . 9 billion to buy out algeta last month . the deal gives bayer full control of xofigo and its blockbuster potential and includes a promising pipeline of similarly targeted therapies .
algeta was valued at nok 775m ( $ 125m ) at ipo in early 2007 – it was acquired by bayer for nok 17 . 6bn ( $ 2 . 9bn ) in march 2014 .
algeta had the biggest gain since 2011 , rising 30 % to close at a record 345 . 20 kroner in oslo . bayer fell 0 . 3 % to close at €95 . 79 .
algeta ' s lead product candidate , alpharadin , addresses a major market opportunity in the field of oncology . bone metastases are a devastating consequence of the progression of certain cancers and current treatments are largely ineffective . healthcap is very excited to be supporting the algeta team in their efforts to develop new therapeutics that target this important unmet medical need ,
said per samuelsson , partner at healthcap .
for further information , please contact : dr . thomas ramdahl ceo algeta asa + 47 23 00 79 90 mark swallow phd / helena podd citigate dewe rogerson + 44 ( 0 ) 207 638 9571
for more : special reports : the top 10 pharma companies by 2013 revenue - bayer healthcare with big 5 , bayer aims for 8 % annual pharma growth through 2016 new drugs in hand , bayer ' s pharma sales leap ahead with a sweetened $ 2 . 9b bid , bayer nabs its xofigo partner , algeta bayer bids $ 2 . 4b for xofigo partner algeta in drive for cancer growth
algeta signed an agreement with bayer for the development and commercialisation of xofigo in september 2009 . under the terms of the agreement , bayer will develop , apply for approvals worldwide and market xofigo globally .
by harnessing the unique characteristics of alpha emitters , such as high potency and short range , algeta is developing new therapeutic candidates and technologies targeting metastatic and disseminated tumors and promising unrivalled potency without unacceptable toxicities .
in december , bayer won backing from the target’s board for an increased $ 2 . 9 billion offer for the norwegian company , which is contingent on bayer being tendered 90 percent of algeta’s share capital .
john berriman , chairman of the board of algeta , said , “we are delighted to have successfully closed this offering , and very pleased to add so many international institutional specialist investors to our shareholder base . ”
algeta , a norwegian developer of treatments for cancer , has officially opened a commercial production facility for xofigo ( radium ra 223 dichloride ) at the institute for energy technology ( ife ) in kjeller , norway .
if you believe consensus , they should pay way more than that , van renterghem said . they should probably pay $ 3 billion . he raised his rating on algeta shares on tuesday to neutral from sell .
algeta asa , headquartered in oslo , norway , is a private therapeutics company dedicated to the development of novel anticancer therapeutics based on alpha particle emitting radionuclides . the company was founded in 1997 as anticancer therapeutic inventions .
thomas ramdahl , president and ceo of algeta , said : “with the recently announced phase ii data demonstrating a survival benefit for our lead product , alpharadin , algeta is at an exciting stage in its development . the funds raised from this offering will now allow us to accelerate the clinical development of alpharadin and advance our pipeline of preclinical product candidates towards the clinic . i look forward with confidence to continued progress in the future .
, a spokesman for bayer , confirmed that the leverkusen , germany - based company made a preliminary offer and declined to comment further . algeta said there’s no guarantee bayer’s proposal will result in a deal , and spokesman
oslo , norway - - ( marketwired - may 30 , 2013 ) - algeta asa ( ose : algeta ) announces that xofigo® ( radium ra 223 dichloride ) injection , recently approved by the us food and drug administration ( fda ) for the treatment of patients with castration - resistant prostate cancer , symptomatic bone metastases and no known visceral metastatic disease , has been launched in the united states and the first sale has been made .
the buzz over bayer ' s final price revolved entirely around xofigo , which is to be expected . but biotech insiders are likely to speculate that bayer also sees value in the work its collaborator was doing on new therapies . algeta was zeroing in on combining thorium - 227 with cancer - targeting antibodies for a next - gen pipeline . and algeta ' s board clearly expected a premium for the experimental work as well as xofigo .
in 2007 algeta completed its ipo on the oslo exchange . we took a small position at that time and engaged in active dialogue with the company . by 2008 , market conditions made it difficult to raise the additional money needed to start the pivotal phase 3 trial . in 2009 , we led a $ 37m financing in algeta having set the condition that the funding had to raise enough capital to complete the trials without a pharmaceutical partner .
bayer is offering algeta shareholders a smaller premium than other biotechnology companies have gotten over the past five years . acquirers paid an average 56 % premium in deals larger than $ 100 million , according to data compiled by bloomberg .
bayer and algeta are already partners in selling the prostate cancer drug xofigo , the use of which was approved by the united states food and drug administration in may . the companies have worked together on developing the drug since 2009 .
gross proceeds from algeta’s initial public offering , subject to completion , will amount to between nok 200 million and nok 250 million and will enable algeta to initiate a phase iii clinical program for alpharadin™ , the company’s lead product . alpharadin™ has , in a double - blind placebo - controlled phase ii clinical trial in patients with late stage prostate cancer , shown statistically significant survival benefit and significant results on various disease progression markers as well as a benign side effect profile .
bayer bid for algeta late last year to gain outright control over novel prostate cancer drug xofigo which the two have developed jointly since 2009 and started selling in the united states in 2013 . the drug also won european approval in november .
bayer has reached an agreement with algeta’s board of directors to make a recommended voluntary public takeover offer to algeta’s shareholders , and is offering them nok 362 per share in cash . the offer implies an equity value of nok 17 . 6 bn ( eur 2 . 1 bn ) and an enterprise value of nok 16 . 2 bn ( eur 1 . 9 bn ) . the offer price represents a premium of 37 % over the closing price on november 25 , 2013 , the day before algeta confirmed that it had received a preliminary , non - binding acquisition proposal from bayer , or a premium of 48 % over the unaffected three - month volume - weighted average share price on november 25 , 2013 .
radiopharmaceuticals specialist algeta asa , of oslo , norway , successfully closed its initial public offering , raising nok 250 million . the offering was more than two times oversubscribed and was in the upper half of the price range at nok 47 per share .
algeta ' s lead product candidate , alpharadin , is a novel bone - seeking experimental radiopharmaceutical based on the alpha particle emitter radium - 223 . alpharadin is currently in phase ii clinical trials as a potential new treatment for bone metastases from prostate cancer .
algeta developed xofigo® ( radium - 223 dichloride ) , a first - in - class , targeted alpha - pharmaceutical that was approved by the us fda and european ema for treatment of patients with symptomatic bone metastases secondary to castration - resistant prostate cancer .
algeta is also developing other technologies for delivering alpha emitters including microparticles , liposomes and its receptor targeting technology , which is designed to enhance the potency of therapeutic antibodies and other tumor - targeting molecules by linking them to the alpha particle emitter thorium - 227 .
bayer and algeta offer patient assistance through xofigo access servicessm which will assist with obtaining coverage and patient support of xofigo . patients and providers may contact the program at 1 - 855 - 6xofigo ( 1 - 855 - 696 - 3446 ) for additional information .
norway ' s algeta ended up negotiating a sales price that was 37 % over the share price it had rung up just ahead of the bid - - in line with the premiums that have been charged for biotech assets over the course of the year .
according to the senior advisor , international focus on the academic results created in norway has increased . she points to the german life science giant bayer ag’s takeover of norwegian biotech algeta in 2014 in a deal worth nok 17 . 6 billion as proof of that .
she refers to øyvind s . bruland and roy h . larsen , who worked on the early development of what would become xofigo and founded algeta in 1997 . since then , they have also helped found the company nordic nanovector in 2009 and oncoinvent the following year .
oncoinvent closed a funding round of its own recently , securing nok 210 million , and in a general sense , the funding environment in norway has improved immensely in recent years – not least due to the sale of algeta and a general recovery of the stock market .
the commercial production of xofigo is underway , and first doses are expected to be ready for patient treatment within a few weeks . bayer has worldwide exclusive marketing rights for xofigo . algeta us , llc and bayer healthcare will co - promote the product in the us .
news of bayer ' s interest in algeta - which developed recently - approved prostate cancer therapy xofigo ( radium ra 223 dichloride ) - first emerged in november when the offer was reported be nok 336 per share , valuing the company at around $ 2 . 4bn .
aside from the promising cancer medicine , algeta also had some 180 full - time employees . a number of those workers went with bayer to germany , while a portion of them stayed in the life science environment around oslo and some have moved on to other biotech companies .
a conference call for investors , analysts and the press , and hosted by algeta ' s senior management team , will take place tomorrow at 08 : 00 cet . to participate in the conference call , please dial the appropriate number below five minutes prior to the call :
the german healthcare giant , through aviator acquisition , a wholly - owned subsidiary of bayer nordic , has offered nok362 ( €43 ; us $ 59 ) per algeta share , in cash , valuing the company at approximately nok17 . 6bn ( us $ 2 . 9bn ) .
abingworth joined the board in 2009 . two us experts were then brought on to the board to oversee clinical and regulatory issues . investor relations advisors were engaged and banking introductions made to help internationalise awareness of the stock . in the first year after our investment the company signed an attractive deal with bayer where algeta retained rights to 50 % of the us market . the trial was well run and stopped early because of signs of overwhelming efficacy . bayer eventually acquired algeta and the drug , xofigo , is now available to patients in the us and europe
' having worked with bayer since 2009 , the board of directors is convinced of bayer’s commitment to establishing xofigo globally , and maximising its blockbuster potential . we are also pleased that bayer intends to further invest in the potential of algeta’s targeted thorium conjugate ( ttc ) research platform . '
oslo , norway , march 9 , 2007 - algeta asa , the norwegian cancer therapeutics company , announced today that the prospectus prepared for the forthcoming ipo and listing on the oslo stock exchange has been approved by ose . the book - building and application period starts monday , 12 march 2007 .
, and buying algeta would mean it doesn’t need to share profits or pay royalties on the medicine . the german drugmaker will probably need to spend more than it’s offering now for its partner , guillaume van renterghem , a london - based analyst for ubs ag , said in a telephone interview .
algeta is the quintessential biotech success story and testament to the range of communications skills and expertise that the citigate team can deploy to cover every likely situation during a company’s life cycle . at each stage , the communications focus was on addressing different challenges and business risks . planning for failure was as important as planning for success . as it was , the team was able to communicate algeta’s success more than its failings , including a major partnering deal with bayer , successful phase 3 results , approval by the regulators in the us and europe , product launch and the company’s eventual acquisition by bayer .
‘the recent approval and launch of xofigo in the us are momentous achievements for algeta and put us firmly on the path to deliver on our vision of becoming a world - class oncology company bringing novel targeted medicines to cancer patients through our leadership in alpha particle - emitting pharmaceuticals , ’ said kay .
algeta had a very intriguing idea . treatment of bone metastases includes irradiation with external x - rays but this is of limited patient benefit . what if you could get the source of radiation inside the bone and kill tumours locally ? radium 223 is a radioactive element that has chemical properties similar to calcium .
under the terms of the agreement , algeta has an option for up to 50 % co - promotion with bayer in the united states under a profit - share arrangement . bayer will commercialize alpharadin globally and pay tiered double - digit royalties on net sales in markets where there is no co - promotion .
germany ' s frankfurter rundschau initially broke the story , but it got the numbers wrong . in a statement , algeta confirmed an offer from bayer but said the bid was for 336 norwegian kroner per share , not 306 kroner , a 27 % premium that would value the company at $ 2 . 4 billion .
advent ' s life sciences team has a first - class investment track record . recent investments include avila therapeutics , biocartis , cellnovo , respivert , thiakis , algeta and amsterdam molecular therapeutics in all of which the advent life sciences team led the formation of the company and / or participated in the first venture round .
bayer’s offer values algeta at about 29 . 1 times earnings before interest , tax , depreciation and amortization , according to data compiled by bloomberg . acquirers of biotechnology companies paid an average of 24 . 4 times profit in deals of $ 100 million or more in the past five years , according to the data . bloomberg
it took a half - billion - dollar sweetener , but bayer has closed the deal to buy its cancer drug partner algeta for $ 2 . 9 billion in cash . the buyout leaves bayer with full control of the prostate cancer drug xofigo along with a pipeline that includes a potential next - gen successor to the targeted radioactive therapy .
andrew kay , algeta’s president & ceo , said : “we are delighted that the fda has taken the decision to approve xofigo so quickly . we are extremely pleased to be able to make this alpha particle - emitting pharmaceutical available to us patients with castration - resistant prostate cancer and symptomatic bone metastases . we will now finalize our launch preparations for xofigo in the us , with the intention of launching it , with bayer , as soon as possible . this approval is a major milestone for algeta and puts us firmly on the path to deliver on our vision to be a world - class oncology company bringing novel targeted medicines to cancer patients through our leadership in alpha particle - emitting pharmaceuticals . ”
the official ribbon cutting ceremony was attended by andrew kay , algeta ' s president and ceo , and senior management colleagues , who were joined by trond giske , the norwegian minister for trade and industry , eva dugstad , president of ife and andreas fibig , president and chairman of the board of management at bayer healthcare pharmaceuticals , and other guests .
earlier this year , bayer happily heralded the fda ' s approval of xofigo for castration - resistant prostate cancer as an important milestone for its steadily growing portfolio of cancer therapies . and now the german pharma company has set its sights on bagging algeta - - the norwegian company that discovered the therapy and subsequently partnered with bayer - - for $ 2 . 4 billion .
concurrent with the financing , per samuelsson , partner , healthcap ; patrick lee , general partner , advent venture partners ; and dr . kent gossett , principal , sr one ; will join stein annexstad , managing director , representing norgesinvestor ; dr . jens petter falck , partner , selvaag venture capital ; and john berriman , chairman ; on algeta ' s board of directors .
now , some analysts say the german pharma may have bid too high , but bayer may well find that algeta was worth the price . the company is working to beef up its oncology presence , and its other cancer partner - - onyx pharmaceuticals , which co - markets stivarga and the older nexavar - - was snapped up by amgen ( $ amgn ) last summer .
algeta ' s president & ceo , andrew kay , commented :
we are delighted to announce the first sale of xofigo , following its approval by the fda for the treatment of patients with castration - resistant prostate cancer , symptomatic bone metastases and no known visceral metastatic disease . for these patients , we anticipate that xofigo will be an important and welcome new addition to the treatment paradigm .
the therapy is used for the treatment of men with castration - resistant prostate cancer ( crpc ) who also have symptomatic bone metastases and no known visceral metastases , and racked up third quarter sales of around €12m ( $ 17m ) in the third quarter . algeta chief executive andrew kay said last month the drug had shown
excellent momentum
thanks to rapid endorsement by the us national cancer network .
alpha emitters have not until recently been a significant therapeutic modality . however , discoveries in radiochemistry and recent advances in the understanding of tumor and radiation biology led algeta ' s scientific founders - - roy larsen and oyvind bruland - - to conceive how the unique features of alpha emitters , such as high potency and short range , could be exploited to create new therapeutic candidates promising unrivalled potency without unacceptable toxicities .
not only has advent secured exits , its investee companies algeta a / s , eusa pharma inc . and uniqure nv have taken products through to approval , parekh noted , saying that underlines the importance of ensuring companies are adequately funded .
we are a big investor and we syndicate . early stage does not mean low cost ; you ' ve got to give companies enough capital ,
he said .
algeta may agree . in a statement , the norwegian company said discussions are at an early stage , and there is
no certainty
that a deal will materialize .
i think this company has great prospects on a standalone basis ,
cfo oystein soug told reuters . he wouldn ' t rule out a bidding war ,
but of course that is not my call ,
he said .
this press release is not for distribution to united states , canada or japan news services or for dissemination in the same countries or elsewhere where such dissemination is not appropriate . this news release is not and under no circumstances is to be construed as a solicitation , offer , or recommendation , to buy or sell securities issued by algeta . this press release may not be relied upon by any person to whom it was not intended to be provided . these materials are not an offer of securities for sale in the united states , canada or japan . securities may not be offered or sold in the united states absent registration or an exemption from registration under the u . s . securities act of 1933 , as amended . algeta asa has not registered , and does not intend to register , any portion of the offering in the united states
this press release is not for distribution to united states , canada or japan news services or for dissemination in the same countries or elsewhere where such dissemination is not appropriate . this news release is not and under no circumstances is to be construed as a solicitation , offer , or recommendation , to buy or sell securities issued by algeta . this press release may not be relied upon by any person to whom it was not intended to be provided . these materials are not an offer of securities for sale in the united states , canada or japan . securities may not be offered or sold in the united states absent registration or an exemption from registration under the u . s . securities act of 1933 , as amended . algeta asa has not registered , and does not intend to register , any portion of the offering in the united states .
john berriman , chairman of the board of algeta , said : “we are delighted to have successfully closed this offering , and very pleased to add so many international institutional specialist investors to our shareholder base . i would like to thank all those involved in the ipo process for their hard work , but special thanks are due to thomas ramdahl and his team for their unstinting efforts since the very early days of the company . ”
bayer plans to strengthen its oncology portfolio with the acquisition of norwegian pharmaceutical company algeta , with which it has already collaborated to develop and commercialize the cancer drug xofigo . the deal , valued at $ 2 . 9 billion , will give bayer full control over xofigo .
we are absolutely convinced of the potential of this drug and the underlying technology to provide patients with innovative treatment options ,
commented bayer ceo marijn dekkers .
first up , algeta is developing thorium - 227 , technology that would allow it to link alpha radiation particles like xofigo to monoclonal antibodies , promising to further improve targeting for future cancer treatments . meanwhile , bayer is spending big to study xofigo in combination with other prostate cancer drugs , including johnson & johnson ' s ( $ jnj ) fast - growing pill zytiga , looking to further expand the market for its banner injection .
algeta ' s lead product candidate , alpharadin , has completed one phase ii trial and is currently in two further phase ii clinical trials as a potential new treatment of hormone refractory prostate cancer . based on results to date , it is expected to progress to clinical phase iii trials . alpharadin is a novel bone - seeking radiopharmaceutical based on the alpha particle emitter radium - 223 and may potentially target skeletal metastases from multiple cancer types .
this news release contains certain forward - looking statements that are based on uncertainty , as they relate to events and depend on circumstances that will occur in the future and which , by their nature , may have an impact on results of operations and the financial condition of algeta . such forward - looking statements reflect our current views and are based on the information currently available to algeta . algeta cannot give any assurance as to whether such forward looking statements will prove to be correct . these forward looking statements include statements regarding our anticipated co - promotion of xofigo in the us . there are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward - looking statements . these factors include , among other things , risks or uncertainties associated with the ability to identify and hire a sufficient number of qualified employees in the us , growth management , general economic and business conditions and the pricing environment , the impact of competition , the ability to successfully commercialize xofigo , the risk that costs associated with the copromotion of xofigo may be greater than anticipated , manufacturing capacity , the risk of non - approval of patents not yet granted , risks in obtaining additional regulatory approvals for radium - 223 and the other risks and uncertainties described in our annual report .
this news release contains certain forward - looking statements that are based on uncertainty , as they relate to events and depend on circumstances that will occur in the future and which , by their nature , may have an impact on results of operations and the financial condition of algeta . such forward - looking statements reflect our current views and are based on the information currently available to algeta . algeta cannot give any assurance as to whether such forward looking statements will prove to be correct . these forward looking statements include statements regarding our co - promotion of xofigo in the us . there are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward - looking statements . these factors include , among other things , risks or uncertainties associated with the ability to identify and hire a sufficient number of qualified employees in the us , growth management , general economic and business conditions and the pricing environment , the impact of competition , the ability to successfully commercialize xofigo , the risk that costs associated with the co - promotion of xofigo may be greater than anticipated , manufacturing capacity , the risk of non - approval of patents not yet granted , risks in obtaining additional regulatory approvals for radium 223 and the other risks and uncertainties described in our annual report .
andrew kay , ceo of algeta , said ,
this agreement is the culmination of an extensive process to establish and deliver the best possible commercialization strategy for alpharadin . in bayer we have selected a world - class oncology company with a proven global track record of launching major cancer products . we are very excited about working with the bayer team to deliver this novel and potentially first choice treatment for cancer patients with bone metastases .
under its deal with bayer , algeta co - promotes xofigo in the u . s . and gets 50 % of the profits in - country ; outside the u . s . , it ' s eligible for royalties and milestone payments on bayer ' s sales . bayer is backing additional clinical trials testing xofigo in combination with johnson & johnson ' s ( $ jnj ) prostate - cancer pill zytiga and with various chemo drugs for other cancers .
after bayer bid $ 2 . 4 billion to buy algeta , some analysts predicted it would need to put down more to snag the oncology company . after all , the norwegian drugmaker discovered xofigo , one of bayer ' s shining growth prospects , and it has some other radiation - based cancer technologies - - including an armed antibody approach - - in the works . so bayer ponied up , chipping in another $ 500 million to seal the deal .
once word of bayer ' s initial $ 2 . 4 billion offer became public weeks ago , analysts expected that bayer would have to up its offer to the $ 3 billion zone if it expected to complete the acquisition . but a few have fretted that the company is paying a bit too much in the deal . algeta had retained co - promotion rights for the drug in the u . s . and had been due royalties on sales in europe .
algeta was also convinced there ' s a second act for xofigo ' s pinpoint alpha - radiation approach to treat cancer . the company has been zeroing in on combining thorium - 227 with cancer - targeting antibodies for a next - gen treatment , offering the potential for a subsequent step - up in its marketing activities . and while a 27 % premium would be considered rather thin this year , with stock prices and valuations up across the board , bayer can afford a bump in the price .
a tie - up would make good sense for bayer , which has been steadily building up its oncology work . the cancer division at bayer includes a partnership on nexavar and the second - generation therapy stivarga , now managed by amgen ( $ amgn ) following the onyx buyout . when algeta signed its $ 800 million collaboration deal with bayer 4 years ago , the savvy norwegian company kept its hands on co - promotion rights in the u . s . while carving out a royalty stream from bayer .
abg sundal collier norge and dnb nor markets acted as joint lead managers and terra securities has acted as co - lead manager . the issue comprises 5 , 319 , 148 new shares , and a further 797 , 852 shares have been allocated under the manager ' s over - allotment option . the issued share capital of algeta asa after the equity offering ( before over - allotment ) will be nok 8 , 231 , 654 , equalling 16 , 463 , 308 shares of nok 0 . 50 par value .
kemal malik , head of global development and member of the bayer healthcare executive committee said ,
we recognize the tremendous potential of algeta ' s alpharadin as a possible treatment for bone metastases in cancer patients - a serious , life - threatening condition . the data we have seen suggest that alpharadin represents a highly targeted treatment option with convenient handling and manageable side effects . bayer is committed to its global oncology franchise and has made significant progress in building a comprehensive pipeline of promising compounds that may provide innovative therapies to cancer patients in need of treatment .
oslo , norway - - ( market wire ) - - september 2 , 2005 - - algeta asa , a therapeutics company dedicated to the development of novel anticancer agents based on alpha particle emitting radionuclides , announced today the closing of a series a round of financing totaling nok 185 million ( euro 23 million / us $ 29 million ) . the funds raised will support the continued development of the company ' s lead product candidate , alpharadin , through its ongoing phase ii clinical trials and into pivotal phase iii trials as a potential new treatment for bone metastases arising from primary prostate cancer .
algeta ' s lead alpha - pharmaceutical candidate , alpharadin ( based on radium - 223 ) , has blockbuster potential for treating bone metastases arising from multiple major cancer types , owing to its bone - targeting nature , potent efficacy ( therapeutic and palliative ) and benign , placebo - like safety profile . development of alpharadin is most advanced targeting bone metastases resulting from hormone - refractory prostate cancer ( hrpc ) , and it entered an international phase iii clinical trial ( alsympca ) in mid - 2008 based on compelling clinical results from a comprehensive phase ii program . this trial is currently open for recruitment .
both of these drugs , however , are part of a partnership with onyx pharmaceuticals ( $ onxx ) , which amgen ( $ amgn ) snapped up in october . when amgen first moved in with its onyx bid , bayer was seen as a rival buyer . that obviously didn ' t come to fruition . algeta is more of a bite - sized deal , and thus would be easier to digest . and it falls within dekkers ' parameters for bolt - on acquisitions - - even if the price goes up to $ 3 billion . whether dekkers also believes bayer has wiggle room on price remains to be seen .
alpharadin is algeta ' s lead cancer therapeutic . it is the first in a new class of alpha - emitting pharmaceuticals ( ' alpha - pharmaceutical ' ) and is based on radium - 223 . alpharadin is in a global phase iii clinical trial ( alsympca ) designed to confirm its efficacy and safety as a targeted treatment for bone metastases in patients with hrpc . alpharadin is administered as a simple injection and has a unique mode of action whereby it targets bone metastases specifically and exerts a highly localized effect on tumor cells while minimizing damage to normal surrounding tissues . in phase ii studies , alpharadin demonstrated strong evidence that it can prolong patient survival , improve quality of life and offer a benign safety profile .
but bayer ' s embrace of algeta ' s cutting - edge approach to oncology is a sign that the old pharma isn ' t married to tradition , and , with ex - partner onyx pharmaceuticals taking a roughly $ 10 . 4 billion deal to join amgen ( $ amgn ) , bayer ' s timing couldn ' t be better . after promising to hone his company ' s oncology focus , bayer ceo marijn dekkers has come through with a blockbuster approval and a multibillion - dollar deal . now we ' ll see whether bayer ' s combination of bright minds and deep pockets can get it into the rare cancer company of roche ( $ rhhby ) , novartis ( $ nvs ) and amgen . - - damian garde ( email | twitter )
this news release contains forward - looking statements and forecasts based on uncertainty , since they relate to events and depend on circumstances that will occur in the future and which , by their nature , will have an impact on results of operations and the financial condition of algeta . there are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward - looking statements . theses factors include , among other things , risks associated with technological development , the risk that research & development will not yield new products that achieve commercial success , the impact of competition , the ability to close viable and profitable business deals , the risk of non - approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products .
advent life sciences closed its first dedicated fund at $ 158 million in 2011 . the final advent diversified fund , which closed in 2006 , so far has produced three new therapeutic products and two medical device products either brought to market by the portfolio companies themselves or their acquirers . some of its big exits or milestones include the $ 350 million acquisition of avila therapeutics by celgene in 2012 ; jazz pharmaceuticals’ $ 650 million purchase of eusa pharma in 2012 ; bayer healthcare’s $ 2 . 9 billion buyout of norwegian cancer drug maker algeta , which closed this year ; and the march 2014 ipo of versartis , of which advent owned 9 . 3 percent after the market debut . shares opened at $ 21 apiece and rose quickly at first , but have come back down below that initial mark , ending monday at $ 19 . 49 .